Schedule M GMP: Are Indian Pharmaceutical Manufacturers Really Ready?

The revision of Schedule M to India’s Drugs and Cosmetics Act represents one of the most consequential regulatory changes for domestic Pharmaceutical manufacturers in recent memory. Notified by the Ministry of Health and Family Welfare, the revised Schedule M aligns Indian GMP requirements substantially more closely with WHO Technical Report Series (TRS) standards — raising the bar across premises, equipment, personnel, documentation, quality management systems, and process control.

As of 2026, compliance is no longer a future obligation — it is a present Regulatory requirement that CDSCO is actively enforcing. The critical question is whether manufacturers are genuinely ready — or whether compliance remains largely a documentation exercise that has not yet translated into a fundamental transformation of manufacturing quality culture.

Genuine Schedule M readiness is not a documentation project. It is an operational transformation that requires investment in people, systems, infrastructure, and culture.

1. What the Revised Schedule M Actually Requires

Quality Management System: A formally documented and operationally embedded QMS — including site master file, product quality review, formal change control, and a demonstrably effective deviation and CAPA management system.

Data Integrity: ALCOA+ principles across all GMP-critical records — both electronic and paper — including audit trail implementation, access control management, and routine audit trail review.

Premises and Equipment: Dedicated areas, environmental controls, formal qualification documentation (IQ/OQ/PQ) for all critical equipment and utilities.

Personnel Competency: Demonstration of competency — not just training completion — for all GMP-critical functions.

Process Validation: All manufacturing processes formally validated, including retrospective or concurrent validation for legacy products.

Supplier and Vendor Management: Approved vendor list, formal supplier qualification programme, and audit and re-qualification cycles for critical raw material suppliers.

2. The Readiness Gap: What Assessments Reveal

Compliance assessments across the Indian Pharmaceutical manufacturing sector consistently reveal the following high-risk deficiencies:

• QMS exists on paper; not operationally embedded — HIGH RISK
• Incomplete audit trail review; manual overwrite practices — CRITICAL RISK
• IQ/OQ/PQ documentation incomplete or outdated — HIGH RISK
• Training records inconsistent; competency not assessed — MEDIUM-HIGH RISK
• Legacy products without formal validation packages — HIGH RISK
• Changes implemented without formal change control — HIGH RISK
• CAPAs open beyond target dates; effectiveness checks absent — MEDIUM-HIGH RISK

3. The Inspection Reality: What CDSCO Is Actually Finding

CDSCO’s inspection programme has intensified significantly. Recurring inspection findings include:

• Repeat observations across consecutive inspection cycles — the same area, the same deviation.
• Data integrity findings: disabled audit trails, shared analyst credentials, OOS results not properly documented.
• Environmental monitoring inadequacies in aseptic manufacturing areas.
• Batch manufacturing records with retrospective entries or non-GMP corrections.
• Manufacturing changes implemented without formal change control review.

CDSCO’s increased inspection rigour is part of a deliberate and well-considered regulatory modernisation programme — one that serves both patient safety and the long-term competitiveness of India’s Pharmaceutical export industry.

4. The International Dimension

Schedule M readiness directly affects export market access:

• CDSCO inspection findings are shared with international Regulatory authorities. A significant CDSCO observation can trigger a USFDA or EMA follow-up inspection.
• WHO prequalification — increasingly required for international tenders — requires full alignment with WHO GMP TRS standards, substantially overlapping with revised Schedule M.
• ASEAN and GCC product registrations frequently require CDSCO GMP certification. A clean compliance record is a commercial asset in export market development.

5. Building Genuine Schedule M Readiness: A Practical Framework

Phase 1 (Months 1-2): Gap Assessment: Commission an independent gap assessment against all revised Schedule M requirements, producing a prioritised gap register with risk ratings and remediation effort estimates.

Phase 2 (Month 2-3): Remediation Planning: Develop a formal remediation plan with assigned ownership, defined timelines, and measurable completion criteria. High-risk gaps must be prioritised for immediate action.

Phase 3 (Months 3-12): Systematic Implementation: Execute the remediation plan with regular progress reviews. Do not allow remediation to be treated as secondary to production pressures.

Phase 4 (Month 11-12): Mock Inspection: Conduct a comprehensive mock inspection led by personnel not directly involved in remediation. Document all observations and address residual gaps before the regulatory inspection.

Phase 5: Sustaining the Quality System: Establish ongoing self-inspection programmes, regular management review cycles, and continuous training and competency verification.

Figure1

Conclusion

The honest answer to whether Indian Pharmaceutical manufacturers are really ready: readiness is highly variable. Companies that achieve authentic compliance maturity — not just documentation readiness — will be better positioned for CDSCO inspections, international regulatory scrutiny, and export market development.

CliniExperts provides Schedule M gap assessments, remediation programme support, mock inspection services, and ongoing compliance management. If your organisation is evaluating its Schedule M readiness, we welcome the opportunity to provide a confidential assessment.